SARS‑CoV‑2 enters human cells by binding

the ACE2 receptor via its spike protein. Genomic surveillance identifies a new

viral variant carrying multiple spike mutations that significantly increase

binding affinity to human ACE2. Laboratory studies show enhanced cell entry and

higher transmission rates in animal and human airway models. Importantly, this

variant shows no reduction in viral stability, replication efficiency, or

disease severity compared to earlier strains.

Assuming sustained human‑to‑human transmission and no

immediate population‑level immunity shift, what outcome is most likely over

time?

CD8⁺ T cells recognise conserved internal influenza proteins

such as NP and M1. Mutations in these regions often reduce viral replication

efficiency. Variants retaining conserved sequences consistently show higher

fitness.

Over long evolutionary timescales, what outcome is most

likely?

Influenza can be transmitted prior to symptom onset. A

mutation extends the duration of pre‑symptomatic viral shedding without

increasing immune detection or compromising replication.

Across many transmission events, what population‑level

effect is most likely?

Influenza viruses undergo antigenic drift via small

mutations in antibody‑binding regions of haemagglutinin. These changes reduce

neutralisation by vaccine‑induced antibodies while leaving

receptor binding intact.

If vaccination coverage remains high over many seasons, what

evolutionary outcome is most likely?

A viral variant shows enhanced replication in the lower

lungs, causing severe pneumonia, but reduced replication in the upper

respiratory tract. Hosts infected with this variant transmit the virus less

effectively before becoming severely ill.

Given sustained circulation attempts in humans, what outcome

is most likely?

Avian influenza viruses preferentially bind α2,3‑linked

sialic acid receptors, whereas human influenza viruses preferentially bind α2,6‑linked receptors found in the upper respiratory tract. In

the scenario where a mutation arises that enhances α2,6‑receptor

binding, increasing upper airway replication and person‑to‑person

transmission of Avian influenza. There is no reduction in viral fitness is

observed due to this mutation.

Given continued circulation in humans, what outcome is most

likely over time?

Seasonal influenza viruses encounter partial population

immunity, whereas pandemic strains emerge in immunologically naïve populations.

A new influenza variant appears with antigenic features poorly recognised by

existing antibodies.

Over multiple epidemic waves, what effect is this most

likely to have?

Most human influenza strains require lung‑specific

proteases to cleave hemagglutinin (HA). A novel mutation allows HA cleavage by

a broader range of host proteases, increasing infectivity without affecting

transmission efficiency or immune recognition.

Assuming this mutation does not increase host mortality

prior to transmission, what is the most likely long‑term outcome?

A hospital reduces empirical antibiotic prescribing,

shortens treatment durations, and favours narrow‑spectrum agents. Over several

years, rates of antibiotic resistance decline despite continued treatment of

infections.

Which change in selection pressure best explains this

outcome?

A mutation causes constitutive overexpression of a multidrug

efflux pump, conferring reduced susceptibility to several antibiotic classes.

The mutation carries a modest metabolic cost but provides survival advantage

during antibiotic exposure.